• Have any questions?
  • info@mpncancerconnection.org
Screen Shot 2016-03-16 at 5.15.52 PMScreen Shot 2016-03-16 at 5.15.52 PMScreen Shot 2016-03-16 at 5.15.52 PMScreen Shot 2016-03-16 at 5.15.52 PM
  • Our Mission
  • About
    • Our team
    • Info
    • David Wallace BioDavid Wallace - MPN Patient Advocate

      David Wallace

      Founder & CEO of MPN Cancer Connection and PV Reporter | Patient Advocate

      When David was diagnosed with PV in 2009, at the age of 47, he soon learned there was limited and often conflicting information available on Myeloproliferative Neoplasms (MPNs). He also realized early on in his diagnosis, the importance of advocating for himself to best manage his polycythemia vera (PV). David was grateful for the early support and guidance of fellow MPN patients on his journey and wanted a way to give back to the MPN community. With a professional background in business administration and sociology, David has a passion for finding solutions and helping others. In 2013, David used his skill set to create PV Reporter,
      a comprehensive patient-focused website for MPNs. David refers to his site as a hub for patients to begin to research their cancer. Whether a patient, caregiver or healthcare provider, PV Reporter offers visitors a wealth of educational resources, patient stories, articles, and the latest news on the treatment for MPNs, helping MPN patients and their caregivers stay informed, connected and empowered. In 2015, along with the help of others, David founded a non-profit MPN Cancer Connection (MPN-CC), a patient-led 501©3 formed to create awareness that MPN patients are “cancer patients” and should have complete access to local and national programs and benefits. David’s philosophy is to educate patients to become their own advocates so that they can make informed decisions on their treatment. David’s dedication to the MPN community is further evidenced through his work and awards:
      • Selected to endorse 2018 NCCN guidelines for MPN patients by MPN Cancer Connection
      • Selected to represent the United States as a patient advocate by MPNs Advocate Network International Conference 2016-2019
      • Recipient of MPN Hero Award 2016
      • Published in MD Anderson Cancer Center MPN Focus Newsletter Fall 2016
      • Appearance on “The Doctors” TV show in 2015 to promote MPN awareness
      • Awarded Press Credentials for American Society of Hematology Conference 2014-2019
      • Contributor to Patient Power MPN educational videos
      David lives in Charlotte, North Carolina. When he’s not working, David enjoys spending time with family, listening to live music, attending outdoor festivals, watching the Carolina Panthers, riding his motorcycle, traveling and of course having his beloved Aussiedoodle Bailey by his side.
  • Resources
    • Partners
    • Corporate Sponsors
    • Groups
  • Our Vision
  • Donate
  • Blog
  • Contact
  • Terms
  • Privacy
  • Partners
  • About
  • Contact
Donate

Clinical Trial Finder

Clinical Trial Finder

Search Results

Dasatinib Holiday for Improved Tolerability

Study Purpose

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of Ph+ chromosome [t(9;22)(q34;q11)].
  • - Ph negative cases or patients with variant translocations who are BCR-ABL positive in multiplex PCR4 will be also considered eligible.
  • - ECOG performance status ≤2.
  • - Age ≥ 18 years old (no upper age limit is given) - Serum levels of potassium, magnesium and total calcium within the normal limits (≥LLN [lower limit of normal] and ≤ULN [upper limit of normal]).
Correction of electrolytes' levels with supplements to meet enrolment criteria is allowed.
  • - AST and ALT ≤2.5 x ULN or 5.0 x ULN if considered due to leukemia.
  • - Alkaline phosphatase ≤2.5 x ULN unless considered due to leukemia.
  • - Total bilirubin ≤1.5 x ULN, except known Gilbert disease.
  • - Serum creatinine ≤2 x ULN.
  • - Written informed consent prior to any study procedures being performed.
For 1st-line patients: • Pre-treatment with hydroxyurea up to 6 months and imatinib or dasatinib for duration of up to 4 weeks is permitted. For ≥ 2nd-line patients: • Patients with treatment failure according to the 2013 ELN Recommendations criteria3 or treatment intolerance as assessed by the investigator after prior treatment with TKIs other than dasatinib (imatinib, nilotinib, bosutinib, ponatinib).

Exclusion Criteria:

  • - Previous allogeneic stem cell transplantation (AlloSCT) - Known impaired cardiac function, including any of the following: - Congenital long QT syndrome.
  • - History of or presence of clinically significant ventricular or atrial tachyarrhythmia.
  • - QTc >450 msec on screening ECG.
  • - Myocardial infarction within 6 months prior to starting therapy.
  • - Other clinical significant heart disease (e.g. unstable angina pectoris, congestive heart failure) - Acute or chronic viral hepatitis with moderate or severe hepatic impairment (Child-Pugh scores >6), even if controlled.
  • - Other concurrent uncontrolled medical conditions (e.g., active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol.
  • - Impaired gastrointestinal function or disease that may alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric by-pass surgery) - Concomitant medications known to be strong inducers or inhibitors of the CYP450 isoenzyme CYP3A4.
  • - Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
  • - Patients who are pregnant or breastfeeding or women of reproductive potential not employing an effective method of birth control.
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to administration of dasatinib. Post-menopausal women must be amenorrheic for at least 12 months in order to be considered of non-childbearing potential. Male and female patients must agree to employ an effective method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  • - Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory) - Active autoimmune disorder, including autoimmune hepatitis.
  • - Known serious hypersensitivity reactions to dasatinib.
  • - Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention.
  • - Patients unwilling or unable to comply with the protocol.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02890784
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University of Jena
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Andreas Hochhaus, Prof.
Principal Investigator Affiliation Jena University Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Germany
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Myeloid Leukemia, Chronic
Additional Details

Dasatinib is indicated in Europe for:

  • - Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
  • - Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.
  • - Ph+ acute lymphoblastic leukemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy Compared to imatinib, dasatinib in CML achieves faster and better responses.
Dasatinib is known for its selected toxicities (fluid retention, edema, pleural effusion, and hematological toxicity) requiring dose reductions or treatment interruptions; these toxicities are more frequent in the first two years of treatment. A randomized dose optimization trial for QD dosing vs.#46; BID dosing has demonstrated non-inferiority with regards to efficacy with an improved toxicity profile. In a pilot study, analyzing patients with dasatinib toxicity, a fixed dasatinib weekend holiday allowed safe toxicity management without impairing efficacy. Furthermore the alternated schedule was also able to improve response parameters in patients that had never achieved an acceptable response prior to the onset of dasatinib holiday dosing schedule. The biological rationale for a holiday dosing schedule is that dasatinib has shown an improved cell death of CML cells even after short exposure times; this improved cell death exceeds the killing rate observed with imatinib in vitro. In summary, the reported preclinical and clinical evidence indicates that efficacy seems to require adequate dasatinib Cmax, while low Cmin (five half-lives between doses) does not impair efficacy nor induces drug resistance. It is speculated that a weekend holiday, allowing a better tolerability, would improve patients' drug adherence. The Investigators hypothesize that a dasatinib holiday schedule (5x100mg+2x0mg weekly) compared to a regular dose (7x100mg weekly) will reduce the rate of clinically significant toxicity (e.g., fluid retention, hematological toxicity, musculoskeletal pain) by 20% observed within the first two years of treatment. The Investigators also hypothesize that the dasatinib holiday schedule is non-inferior to dasatinib regular dose in achieving the European LeukemiaNet (ELN) recommended levels of response within the first 24 months.

Arms & Interventions

Arms

Active Comparator: A. Standard arm

100mg dasatinib (SPRYCEL®) daily dose (QD) (7x100) (Standard therapy)

Experimental: B. Study arm

100mg dasatinib (SPRYCEL®) (QD) weekdays (1-5) only (5x100+2x0) (overall dose reduction per week)

Interventions

Drug: - dasatinib (SPRYCEL®)

Treatment optimization for patients with chronic myeloid leukemia (CML)

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Uniklinik der RWTH Aachen, Aachen, Germany

Status

Recruiting

Address

Uniklinik der RWTH Aachen

Aachen, , 52074

Site Contact

Martina Crysandt, Dr. med.

dasahit@med.uni-jena.de

0241 #8035641

Gesundheitszentrum St. Marien GmbH, Amberg, Germany

Status

Recruiting

Address

Gesundheitszentrum St. Marien GmbH

Amberg, , 92224

Site Contact

Ludwig Fischer von, Dr. med.

dasahit@med.uni-jena.de

+49 #9621-381 637

Gemeinschaftspraxis Dres. Klausmann, Aschaffenburg, Germany

Status

Recruiting

Address

Gemeinschaftspraxis Dres. Klausmann

Aschaffenburg, , 63739

Site Contact

Martine Klausmann, Dr. med.

dasahit@med.uni-jena.de

+49 #6021-342780

OnkoBer, Berlin, Germany

Status

Recruiting

Address

OnkoBer

Berlin, , 10115

Site Contact

Andreas Josting, Prof.

dasahit@med.uni-jena.de

+49 30 #4990 7070

Evangelisches Klinikum Bethel gGmbH, Bielefeld, Germany

Status

Recruiting

Address

Evangelisches Klinikum Bethel gGmbH

Bielefeld, , 33611

Site Contact

Kristin Sauerland, Dr. med.

dasahit@med.uni-jena.de

0521 #772 75769

Universitätsklinikum Bonn, Bonn, Germany

Status

Recruiting

Address

Universitätsklinikum Bonn

Bonn, , 53111

Site Contact

Dominik Wolf, Prof. Dr.

dasahit@med.uni-jena.de

+49 #228-287 15229

Klinikum Bremen-Mitte gGmbH, Bremen, Germany

Status

Recruiting

Address

Klinikum Bremen-Mitte gGmbH

Bremen, , 28177

Site Contact

Bernd Hertenstein, Prof. Dr.

dasahit@med.uni-jena.de

+49 3641 939 6661

Klinikum Chemnitz gGmbH, Chemnitz, Germany

Status

Recruiting

Address

Klinikum Chemnitz gGmbH

Chemnitz, , 09113

Site Contact

Mathias Hänel, PD Dr. med.

dasahit@med.uni-jena.de

+49 #371-33343045

Gemeinschaftspraxis Mohm/Prange-Krex, Dresden, Germany

Status

Recruiting

Address

Gemeinschaftspraxis Mohm/Prange-Krex

Dresden, , 01307

Site Contact

Johannes Mohm, Dr. med.

dasahit@med.uni-jena.de

+49 #351-4416018

Dresden, Germany

Status

Recruiting

Address

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

Dresden, , 01307

Site Contact

Rainer Ordemann, Prof. Dr.

dasahit@med.uni-jena.de

+49 3641 939 6661

Helios St. Johannes Klinik Duisburg, Duisburg, Germany

Status

Recruiting

Address

Helios St. Johannes Klinik Duisburg

Duisburg, , 47166

Site Contact

Michael Heinsch, Dr. med.

dasahit@med.uni-jena.de

0203 #546 0

Gemeinschaftspraxis Erlangen, Erlangen, Germany

Status

Recruiting

Address

Gemeinschaftspraxis Erlangen

Erlangen, , 91052

Site Contact

Babette Häcker, Dr. med.

dasahit@med.uni-jena.de

09131 #762552

Universitätsklinikum Essen, Essen, Germany

Status

Recruiting

Address

Universitätsklinikum Essen

Essen, , 45147

Site Contact

Joachim Göthert, Dr. med.

dasahit@med.uni-jena.de

+49 #201-723 2553

Universitätsklinikum Frankfurt, Frankfurt, Germany

Status

Recruiting

Address

Universitätsklinikum Frankfurt

Frankfurt, , 60590

Site Contact

Fabian Lang, Dr. med.

dasahit@med.uni-jena.de

+49 #69 6301 4013

Universitätsklinikum Freiburg, Freiburg, Germany

Status

Recruiting

Address

Universitätsklinikum Freiburg

Freiburg, , 79106

Site Contact

Nikolas von Bubnoff, Prof. Dr.

dasahit@med.uni-jena.de

0761 #270 36710

Katholisches Karl-Leisner Klinikum, Goch, Germany

Status

Recruiting

Address

Katholisches Karl-Leisner Klinikum

Goch, , 47574

Site Contact

Volker Runde, Prof. Dr.

dasahit@med.uni-jena.de

+49 #2823 891447

MVZ Onkologische Kooperation Harz, Goslar, Germany

Status

Recruiting

Address

MVZ Onkologische Kooperation Harz

Goslar, , 38642

Site Contact

Mark-Oliver Zahn, Dr. med.

dasahit@med.uni-jena.de

05321 #686 118

ConMed GmbH, Göttingen, Germany

Status

Recruiting

Address

ConMed GmbH

Göttingen, , 37073

Site Contact

Michael Metz, Dr. med.

dasahit@med.uni-jena.de

0551 #485925

Halberstadt, Germany

Status

Recruiting

Address

Hämato-Onkologische Gemeinschaftspraxis Halberstadt

Halberstadt, , 38820

Site Contact

Christian Maas, Dr. med.

dasahit@med.uni-jena.de

+49 3641 939 6661

Universitätsklinikum Halle/S., Halle, Germany

Status

Recruiting

Address

Universitätsklinikum Halle/S.

Halle, , 06120

Site Contact

Haifa Al-Ali, PD Dr. med.

dasahit@med.uni-jena.de

0345 #557 4959

Asklepios MVZ Onkologie, Hamburg, Germany

Status

Recruiting

Address

Asklepios MVZ Onkologie

Hamburg, , 22417

Site Contact

Svenja Neumann, Dr. med.

dasahit@med.uni-jena.de

040 #181887 9241

MediProjekt GbR, Hannover, Germany

Status

Recruiting

Address

MediProjekt GbR

Hannover, , 30171

Site Contact

Michael Koenigsmann, Prof. Dr.

dasahit@med.uni-jena.de

+49 3641 939 6661

St. Bernward Krankenhaus Hildesheim, Hildesheim, Germany

Status

Recruiting

Address

St. Bernward Krankenhaus Hildesheim

Hildesheim, , 31134

Site Contact

Ulrich Kaiser, Prof. Dr.

dasahit@med.uni-jena.de

05121 #90 1863

Universitätsklinikum Jena, Jena, Germany

Status

Recruiting

Address

Universitätsklinikum Jena

Jena, , 07740

Site Contact

Andreas Hochhaus, Prof. Dr.

dasahit@med.uni-jena.de

+49 #36419324201

Kaiserslautern, Germany

Status

Recruiting

Address

Institut für med. Dokumentation, Gutachtenstellung, Gesundheitsförderung und Qualitätssicherung GbR

Kaiserslautern, , 67655

Site Contact

Richard Hansen, Prof. Dr.

dasahit@med.uni-jena.de

+49 3641 939 6661

Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany

Status

Recruiting

Address

Städtisches Klinikum Karlsruhe gGmbH

Karlsruhe, , 76133

Site Contact

Margarethe Schmier, Dr. med.

dasahit@med.uni-jena.de

+49 #721-974 3050

St. Vincentius-Kliniken Karlsruhe, Karlsruhe, Germany

Status

Recruiting

Address

St. Vincentius-Kliniken Karlsruhe

Karlsruhe, , 76137

Site Contact

Michael Schatz, Dr. med.

dasahit@med.uni-jena.de

0721 #8108 3003

Onkologische Gemeinschaftspraxis, Kassel, Germany

Status

Recruiting

Address

Onkologische Gemeinschaftspraxis

Kassel, , 34119

Site Contact

Ulrike Söling, Dr. med.

dasahit@med.uni-jena.de

0561 #7393 372

Klinikum Kassel, Kassel, Germany

Status

Recruiting

Address

Klinikum Kassel

Kassel, , 34125

Site Contact

Martin Wolf, Prof. Dr.

dasahit@med.uni-jena.de

0561 #9803504

Städtisches Krankenhaus Kiel GmbH, Kiel, Germany

Status

Recruiting

Address

Städtisches Krankenhaus Kiel GmbH

Kiel, , 24116

Site Contact

Roland Repp, Prof. Dr.

dasahit@med.uni-jena.de

+49 3641 939 6661

Universitätsklinikum Schleswig-Holstein, Kiel, Germany

Status

Recruiting

Address

Universitätsklinikum Schleswig-Holstein

Kiel, , 24116

Site Contact

Björn-Niklas Heydrich, Dr. med.

dasahit@med.uni-jena.de

+49 #431-16971297

InVo Institut für Versorgungsforschung, Koblenz, Germany

Status

Recruiting

Address

InVo Institut für Versorgungsforschung

Koblenz, , 56068

Site Contact

Jörg Thomalla, Dr. med.

dasahit@med.uni-jena.de

0261 #921569325

MVZ Hämatologie und Onkologie, Krefeld, Germany

Status

Recruiting

Address

MVZ Hämatologie und Onkologie

Krefeld, , 47805

Site Contact

André Lollert, Dr. med.

dasahit@med.uni-jena.de

02151 #780 250

Onkologische Schwerpunktpraxis, Kronach, Germany

Status

Recruiting

Address

Onkologische Schwerpunktpraxis

Kronach, , 96317

Site Contact

Martina Stauch, Dr. med.

dasahit@med.uni-jena.de

09261 #62480

Onkologisches Zentrum, Lebach, Germany

Status

Recruiting

Address

Onkologisches Zentrum

Lebach, ,

Site Contact

Stephan Kremers, Dr. med.

dasahit@med.uni-jena.de

06881 #501500

Studienzentrum UnterEms, Leer, Germany

Status

Recruiting

Address

Studienzentrum UnterEms

Leer, , 26789

Site Contact

Carsten Janßen

dasahit@med.uni-jena.de

0491 #98791203

Universitätsklinikum Leipzig, Leipzig, Germany

Status

Recruiting

Address

Universitätsklinikum Leipzig

Leipzig, , 04103

Site Contact

Dietger Niederwieser, Prof. Dr.

dasahit@med.uni-jena.de

+49 #341-9713131

Universitätsmedizin Mannheim, Mannheim, Germany

Status

Recruiting

Address

Universitätsmedizin Mannheim

Mannheim, , 68169

Site Contact

Susanne Saußele, Prof. Dr.

dasahit@med.uni-jena.de

+49 #621-383-6966

Marburg, Germany

Status

Recruiting

Address

Universitätsklinikum Gießen und Marburg GmbH

Marburg, , 35043

Site Contact

Andreas Burchert, Prof. Dr.

dasahit@med.uni-jena.de

06421 #586 5611

Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany

Status

Recruiting

Address

Stauferklinikum Schwäbisch Gmünd

Mutlangen, , 73557

Site Contact

Holger Hebart, Prof. Dr.

dasahit@med.uni-jena.de

+49 #7171-701-1302

Rotkreuzklinikum München, München, Germany

Status

Recruiting

Address

Rotkreuzklinikum München

München, , 80634

Site Contact

Marcus Hentrich, Prof. Dr.

dasahit@med.uni-jena.de

089 #13034372

München, Germany

Status

Recruiting

Address

Gemeinschaftspraxis Hämatologie/ Onkologie

München, , 81241

Site Contact

Matthias Zingerle, Dr. med.

dasahit@med.uni-jena.de

+49 3641 939 6661

Universitätsklinikum Münster, Münster, Germany

Status

Recruiting

Address

Universitätsklinikum Münster

Münster, , 48149

Site Contact

Eva Eßeling, Dr. med.

dasahit@med.uni-jena.de

+49 #251- 8349963

Neustadt Am Rübenberge, Germany

Status

Recruiting

Address

Hämatologisch-onkologische Schwerpunktpraxis

Neustadt Am Rübenberge, , 31535

Site Contact

Barbara Tschechne, Dr. med.

dasahit@med.uni-jena.de

+49 5032 #89127 230

Klinikum Passau, Passau, Germany

Status

Recruiting

Address

Klinikum Passau

Passau, , 94032

Site Contact

Thomas Südhoff, Prof. Dr.

dasahit@med.uni-jena.de

+49 #854-5300 2356

Kreiskliniken Reutlingen GmbH, Reutlingen, Germany

Status

Recruiting

Address

Kreiskliniken Reutlingen GmbH

Reutlingen, , 72764

Site Contact

Alexander Wacker, Dr. med.

dasahit@med.uni-jena.de

+49 #7121-2003988

Universitätsmedizin Rostock, Rostock, Germany

Status

Recruiting

Address

Universitätsmedizin Rostock

Rostock, , 18057

Site Contact

Christian Junghanß, Prof. Dr.

dasahit@med.uni-jena.de

+49 #381-4947421

Klinikum Südstadt Rostock, Rostock, Germany

Status

Recruiting

Address

Klinikum Südstadt Rostock

Rostock, , 18059

Site Contact

Beate Krammer-Steiner, Dr. med.

dasahit@med.uni-jena.de

+49 #381-4401 6100

Hämatologie-Onkologie Stolberg, Stolberg, Germany

Status

Recruiting

Address

Hämatologie-Onkologie Stolberg

Stolberg, , 52222

Site Contact

Matthias Groschek

dasahit@med.uni-jena.de

02402 #7668829

Klinikum Mutterhaus der, Trier, Germany

Status

Recruiting

Address

Klinikum Mutterhaus der

Trier, , 54290

Site Contact

Rolf Mahlberg, Dr. med.

dasahit@med.uni-jena.de

+49 #651-947-2571

Universitätsklinikum Ulm, Ulm, Germany

Status

Recruiting

Address

Universitätsklinikum Ulm

Ulm, , 89081

Site Contact

Frank Stegelmann, Dr. med.

dasahit@med.uni-jena.de

+49 3641 939 6661

Villingen-Schwenningen, Germany

Status

Recruiting

Address

Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH

Villingen-Schwenningen, , 78052

Site Contact

Paul La Rosée, Prof. Dr.

dasahit@med.uni-jena.de

+49 3641 939 6661

Rems-Murr-Klinik Winnenden, Winnenden, Germany

Status

Recruiting

Address

Rems-Murr-Klinik Winnenden

Winnenden, , 71364

Site Contact

Stefani Parmentier, Dr. med.

dasahit@med.uni-jena.de

+49 7195 #59136022

Powered By
The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Recent Posts

  • Contemporary Approach CALR Positive MPNs
  • 9 Tips to Reduce MPN Fatigue
  • Common Clinical Trial Acronyms and Abbreviations
  • Understanding the Phases of Clinical Trials
  • 4th Angel providing one-on-one support services for MPN Patients
  • Serving the MPN cancer community with support services




Sign up for our Newsletter

Subscribers will receive updates from MPN-CC and PV Reporter!
* = required field

RSS News

  • Inflammatory Microenvironment & Specific T-Cells in MPNs
  • Covid-19 Vaccines FAQs for Patients and Caregivers
  • Precision Medicine and Gene Mutations in MPNs
  • New MPN Drug Treatments in Development
© 2021 MPN Cancer Connection. All Rights Reserved.
  • Terms
  • Privacy
  • Partners
  • About
  • Contact
MPN Cancer Connection
Malcare WordPress Security